Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.

Frost, Nikolaj; Zhamurashvili, Tamar; von Laffert, Maximilian; Klauschen, Frederick; Ruwwe-Glösenkamp, Christoph; Raspe, Matthias; Brunn, Matthias; Ochsenreither, Sebastian; Temmesfeld-Wollbrück, Bettina; Suttorp, Norbert; Grohé, Christian; Witzenrath, Martin

Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.

Frost, Nikolaj; Zhamurashvili, Tamar; von Laffert, Maximilian; Klauschen, Frederick; Ruwwe-Glösenkamp, Christoph; Raspe, Matthias; Brunn, Matthias; Ochsenreither, Sebastian; Temmesfeld-Wollbrück, Bettina; Suttorp, Norbert; Grohé, Christian; Witzenrath, Martin.

Afiliación

Frost N; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. Electronic address: nikolaj.frost@charite.de.
Zhamurashvili T; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
von Laffert M; Department of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Klauschen F; Department of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Ruwwe-Glösenkamp C; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Raspe M; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Brunn M; Hospital Königin-Elisabeth-Herzberge, Berlin, Germany.
Ochsenreither S; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Temmesfeld-Wollbrück B; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Suttorp N; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Grohé C; Klinik für Pneumologie, Evangelische Lungenklinik Berlin Buch, Berlin, Germany.
Witzenrath M; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Division of Pulmonary Inflammation, Charité-Universitätsmedizin Berlin, corpo

Clin Lung Cancer ; 21(6): e607-e621, 2020 11.

Article en En | MEDLINE | ID: mdl-32620471

Asunto(s)

Adenocarcinoma del Pulmón/tratamiento farmacológico; Quinasa de Linfoma Anaplásico/genética; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Proteínas de Unión al ADN/metabolismo; Neoplasias Pulmonares/tratamiento farmacológico; Factores de Transcripción/metabolismo; Adenocarcinoma del Pulmón/genética; Adenocarcinoma del Pulmón/metabolismo; Adenocarcinoma del Pulmón/patología; Anciano; Quinasa de Linfoma Anaplásico/metabolismo; Carboplatino/administración & dosificación; Cisplatino/administración & dosificación; Proteínas de Unión al ADN/genética; Desoxicitidina/administración & dosificación; Desoxicitidina/análogos & derivados; Receptores ErbB/genética; Receptores ErbB/metabolismo; Femenino; Estudios de Seguimiento; Reordenamiento Génico; Humanos; Neoplasias Pulmonares/genética; Neoplasias Pulmonares/metabolismo; Neoplasias Pulmonares/patología; Masculino; Análisis por Apareamiento; Persona de Mediana Edad; Mutación; Pemetrexed/administración & dosificación; Pronóstico; Puntaje de Propensión; Estudios Retrospectivos; Tasa de Supervivencia; Factores de Transcripción/genética; Gemcitabina

Palabras clave

Nonsmall-cell lung cancer; Pemetrexed; Platinum-based chemotherapy; Predictive factor; Propensity-score matching

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Factores de Transcripción / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas de Unión al ADN / Adenocarcinoma del Pulmón / Quinasa de Linfoma Anaplásico / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lung Cancer Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google